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ABSTRACT
Alternative splicing of the p53 transcript which so far
has been demonstrated only in the murine system has
been proposed as a general regulatory mechanism for
the generation of functionally different p53 proteins.
We analyzed by RT-PCR the pattern of p53 mRNAs
within the region spanning exons 10 and 11 of the p53
gene in 13 different tissues from two independent
mouse strains, in 10 different rat tissues and in six
different human tissues. PCR products of the expected
sizes, corresponding to the normally spliced and the
alternatively spliced p53 mRNAs, were detected in
mice. Alternatively spliced mRNA was found at
-25-30% the level of the normally spliced p53 mRNA in
most tissues analyzed. In spleen and kidney the
proportion of alternatively spliced p53 mRNA was
much lower. Surprisingly, examination of p53 mRNAs
isolated from 10 different rat tissues and six human
tissues within the same region of the p53 gene showed
only products of normal size. Although a potential
homologous alternative 3' splice site within intron 10
of the human p53 gene is present in the genomic
sequence of human p53, the expected corresponding
alternatively spliced p53 mRNA was undetectable.
These findings imply that the generation of functionally
different forms of p53 by alternative splicing of p53
transcripts is a species-specific event, possibly indi-
cating species-specific mechanisms for regulating p53
activities.
INTRODUCTION
The tumor suppressor p53 is a multifunctional protein, exerting
a variety of different activities which are all related to protecting
the cells of vertebrates against the disastrous consequences of
DNA damage (1,2). The so far most prominent activity of p53 is
that of a sequence-specific transcription factor that can positively
or negatively regulate a set of genes involved in growth control,
DNA repair and initiation of apoptosis or cell death (3). In
addition, p53 seems to directly 'sense' damaged DNA (4,5) and
promote the annealing of complementary single-stranded RNA
and DNA (6,7). RNA re-annealing has very recently been
identified as an important activity in p53-mediated translational
control of mRNAs with extensive secondary structure (8). DNA
annealing might be important for preventing unscheduled
recombination promoted by single-stranded DNA intermediates
initiating recombination (9,10).
The p53 protein has been structurally and functionally divided
into three domains, separated by hinge regions (11-14). The
N-terminal 42 amino acids harbor the p53 transactivation domain
(15). The central core domain of p53, spanning amino acids
120-290, mediates sequence-specific DNA binding to p53
consensus DNA elements (11-14). The C-terminal domain of
p53, comprising amino acids 311-393, contains the nuclear
localization signals of p53 (16), the p53 oligomerization domain
(17) and a domain mediating the non-sequence-specific interac-
tion of p53 with DNA and RNA (18,19). This domain is also
responsible for the complementary single-strand nucleic acid
annealing activity mentioned above (6,7). In addition, these
domains are targets of an increasing number of viral and cellular
proteins (20-22). The C-terminus has outstanding properties
insofar as it not only harbors a variety of important properties of
p53, as described above, but also represents the major regulatory
domain of the p53 molecule, modulating sequence-specific DNA
binding of the central core domain of p53 (23) and, together with
this central domain, acting as a sensor for damaged DNA (4,5).
In line with its regulatory function, the C-terminal domain of p53
contains several phosphorylation sites, thus providing targets for
the modulation of p53 activities by cellular kinases (24).
At yet another level of regulation, the alternative use of two
exons at the 3'-end of the mouse n53 gene has been proposed
(25-27). Alternative splicing of the primary p53 transcript
generates two distinct p53 mRNAs and two distinct p53 proteins,
the full-length normal splice (NS) p53 and an alternative splice
(AS) p53, in which 17 new amino acids substitute for the last 26
C-terminal amino acids of the NS p53 (28,29). Functionally the
AS p53 protein differs from the NS p53 protein in that it is
constitutively active in sequence-specific DNA binding (30), but
lacks the intrinsic annealing activity for single-strand nucleic
acids (31). Han and co-workers (25,26) detected the AS p53
mRNA species at -25-33% of the level of the NS p53 mRNA in
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both normal murine epidermal and carcinoma cells, as well as in
mouse 10T1/2 fibroblast cells, mouse liver and testis tissues.
Furthermore, it has been found that different levels of NS and AS
p53 mRNAs are present at different phases of the cell cycle (26),
supporting the idea that alternative splicing might provide an
important means for regulating p53 activity.
All vertebrate species analyzed so far, regardless of their
evolutionary distance, share a high identity at the protein level, as
well as a striking similarity at the level of genomic organization
of the p53 gene (sizes of the exons and the locations of splice
junctions; 32). Hence the existence of similar control mechan-
isms of p53 gene expression in vertebrates is rather likely. In this
study we performed extensive p53 mRNA analyses to determine
whether alternative splicing of the p53 transcript, and hence the
generation of two functionally distinct p53 proteins, is a general
phenomenon in mammalian tissues. Alternative splicing of the
p53 transcript was detected in mouse cells and tissues, but not in
rat and human. We therefore conclude that alternative splicing of
the p53 transcript is a species-specific event.
MATERIALS AND METHODS
Source of tissue specimens
Organs were isolated from BALB/c and DBA mice at days 25 and
40, as well as from Wistar rats at day 40 (Table 1). Professor
J. Schmidtke and F. Schnieders (Medizinische Hochschule Han-
nover, Hannover, Germany) kindly provided us with human
tissue specimens from colon, epidermis, kidney, lung and thyriod
gland, as well as with three separate testis specimens. Two
separate ovary specimens were provided by the Max-Delbriick-
Centrum fur Molekulare Medizin (Berlin-Buch, Germany).
cDNA analysis
Total RNAs were extracted by the guanidinium-HCl thiocyanate/
phenol/chloroform method (33). As a quality check for the
prepared murine RNA aliquots of all RNA samples were
converted to cDNA using primer 3GAP within the non-translated
region of the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene (34; CGAAAGCTTTAGGCCCCTCCTGTTA-
TT). Subsequently the resulting cDNA was amplified using
primers 3GAP and 5GAP (CGAGGATCCACAGCCGCATCT-
TCTTGT) under standard amplification conditions (35), leading
to amplification of the full-length GAPDH cDNAs.
Aliquots of all RNA samples were converted to cDNA using a
First-Strand-cDNA kit (Pharmacia, Upsala, Sweden) according to
the manufacturer's protocol. Locations of the cDNA primers used,
p96-l (human, TGTCAGTGGGGAACAAGAAGTGG), Rp53-3
(rat, GGACTAGCATTGTCTTGTCAGC) and Mp53-2 (mouse,
AGTCGGATCCAGGGTGGGGGGTGGATA), are shown in
Figure 1A.
Amplification
The annealing temperatures were optimized with genomic
DNAs. PCR reactions were carried out in principle as described
elsewhere (35). Following a 10 min denaturation at 94°C, 30
PCR cycles [denaturation, 0.5 min, 94°C; annealing, 1 min, 58°C
(rat and human), 60°C (mouse); elongation, 1 min, 72°C] were
performed using the following primer combinations: human,
p96-l and p96-2 (TTGGAACTCAAGGATGCCCAGG) or
p53 cDNA
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Figure 1. (A) Schematic representation of the homologous p53 cDNA
fragments, including exons 10 and 11 and part of the non-translated region of
the p53 gene. RT-PCR analysis of a p53 transcript spanning this region was
performed with the indicated pairs of oligonucleotide primers. (B) Analysis of
RT-PCR products derived from normally and alternatively spliced p53
transcripts. RT-PCR products were electrophoresed through 2% agarose gels.
Lane 1, human testis (170 bp); lane 2, rat testis (270 bp); lane 5, murine kidney
(517 bp); lane 6, murine spleen (517 bp); lane 7, murine testis (517 bp).
RT-PCR products in lanes 1-6 correspond to the normally spliced p53
transcripts. As a representative of a derivative of the alternatively spliced
transcript lane 7 shows an additional PCR product, 613 bp in length, present in
the murine testis sample. Lanes 3 and 4, markers.
p96-l and A4 (GACGGAACAGCTTTGAGGT); rat, Rp53-3
and Rp53-1 (ATGTTCCGAGAGCTGAATGAGG); mouse,
Mp53-2 and Mp53-1 (AGTCGAATTCAAGGATGCCCATGC-
TAC) (Fig. 1 A). Final extension was at 72°C for 10 min.
The presence of the alternatively spliced p53 transcripts was
confirmed by PCR using standard PCR conditions (see above; 30
PCR cycles: denaturation, 30 s, 94°C; annealing, 1 min, 60°C;
elongation, 1 min, 72°C) with primer Mp53-1 within exon 10 of
the murine p53 gene and primer Mp96-1 from within the inserted
sequence (GCTTTCCTCCTTGATCAAGG).
RT-PCRs specific for the hypothetically included sequence in
AS human p53 mRNA were performed with primer p96-4,
including the sequence of the 3' boundary of the last exon
(TCCCTGACCAATGCTTTGAAGG), and primer p96-2, from
within exon 10 (Fig. 2) using standard PCR conditions (see
above; 30 PCR cycles: denaturation, 1 min, 94°C; annealing,
1 min, 58°C; elongation, 2 min, 72°C).
PCR product analysis
The amplified PCR products were separated by agarose gel
electrophoresis and characterized by restriction digestion.
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Figure 2. Hypothetical alternative splicing within intron 10 of the human p53 gene. Alternative splicing would lead to an insertion of 94 bp between exons 10 and
11. In this case RT-PCR using primers p96-2 and p96-1 should generate two separate PCR products 170 and 264 bp in length. RT-PCR using primer p96-4 from the
94 bp sequence and primer p96-2 from within exon 10 in human genomic DNA would yield a PCR product of 914 bp. RT—PCR should lead to amplification of an
88 bp PCR product.
Hybridization using oligonucleotide Mp53-1 as a probe was
performed to quantitate the relative amount of the different PCR
products by densitometry following standard conditions (36). Ten
percent of the total RT-PCR was subjected to electrophoresis
through a 2% agarose gel, stained with ethidium bromide and
blotted onto N+-Nylon membrane (Amersham) in the presence of
0.4 N NaOH. Hybridization with [y-32P]dATP-labeled oligo-
nucleotide Mp53-1 was performed for 3 h at 65 °C, followed by
two washes with 2x SSPE, 0.1% Triton X-100 at room
temperature and two washes at 65°C with the same solution.
Autoradiographs were analyzed by densitometry.
RESULTS
Tissue-specific splicing of the p53 transcript in mouse
tissues
To determine whether alternative splicing of murine p53 tran-
scripts depends on tissue type, mouse strain or sex of the animals
we first analyzed the pattern of p53 mRNAs spanning the region
of the p53 gene between exons 10 and 11 in 13 different mouse
tissues (Table 1). The tissues were isolated from BALB/c and
DBA mice at days 25 and 40, respectively. Total RNA was
extracted from tissue specimens using the guanidinium-HCl
thiocyanate/phenol/chloroform method (33). As a quality check
for the prepared RNA, aliquots of all RNA samples were
converted to cDNA using primer 3GAP within the GAPDH gene
(34). The resulting cDNA was subsequently amplified using
primers 3GAP and 5GAP of the GAPDH gene (see Materials and
Methods) and led to amplification of the full-length GAPDH
cDNA (data not shown). Aliquots of these RNA samples were
then converted to cDNA using primer Mp53-2 within the
non-translated region of the p53 gene, followed by PCR
amplification using the same primer and primer Mp53-1 located
in exon 10 of the p53 gene (Fig. 1 A). Two PCR products of the
expected sizes, 517 and 613 bp in length (25), were detected,
corresponding to NS and AS murine p53 mRNA (Fig. IB, lane
7). With the exception of spleen and liver (discussed below), AS
p53 mRNA, as determined by densitometry, was present in these
tissues at -25-30% of the level of NS p53 mRNA, in accordance
with the data published by Han and Kulesz-Martin (25,26). The
proportions of these mRNAs did not differ significantly between
the mouse strains analyzed and were independent of the sex of the
animals. Furthermore, the proportions of alternatively spliced
p53 transcripts were similar at days 25 and 40 (data not shown).
In contrast, using the same RT-PCR approach we found that the
level of alternatively spliced p53 transcripts was much lower in
spleen and kidney samples than that determined in all other
tissues analyzed (Fig. IB, lanes 5 and 6). Nevertheless, in these
tissues also the presence of the alternatively spliced p53
transcripts was confirmed by PCR, using primers located within
exon 10 (Mp53-1) and from within the inserted sequence (M96-1)
followed by restriction digestion {Bed) of the obtained PCR
products (data not shown). All data were reproducible in repeated
experiments, indicating a tissue-specific splicing of p53 tran-
scripts in mice.
Table 1. Alternative splicing events within intron 10 of the p53 transcripts
obtained by RT-PCR analysis of RNAs from various tissue types and species
Origin of transcripts Mouse Rat Human
DBA Balb/c
Colon
Small intestine
Epidermis
Bladder
Kidney
Testis
Liver
Lung
Thymus
Heart
Spleen
Ovary
Brain
/, not determined; +, alternative splicing found; o, alternative splicing found at
low level; - , alternative splicing not found.
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Analysis of rat and human tissues for alternative
splicing near the 3'-end of the p53 gene
Sequence data from Hulla and Schneider (37) provided evidence
that the rat p53 gene differs from other p53 gene structures.The
newly defined rat p53 gene consists of only 10 exons and 9
introns, because no intervening sequence is present between the
region of the rat gene corresponding to exons 6 and 7 of the mouse
and human p53 genes. Thus exons 6 and 7 are combined, forming
exon 6 in the rat gene. However, for clarity homologous exon
regions of the p53 genes of mouse, human and rat were assigned
the same numbers throughout this study.
Total RNAs from 10 different tissues of Wistar rats (Table 1) were
isolated as described above. p53-specific RNA was subsequently
amplified by RT-PCR using primers of exon 10 (Rp53-1) and from
within the non-translated region of the rat p53 gene (Rp53-3; Fig.
1 A). Thirty rounds of PCR were sufficient for amplification of large
amounts of PCR products 270 bp in length, as expected for NS p53
from the published sequence of the rat p53 gene (37). No further
PCR products were detected using this approach (Fig. 1B, lane 2),
suggesting that the alternatively spliced p53 products were
expressed at a rather low level, if alternative splicing would occur
at all, within this region of the rat p53 transcript.
Similar experiments were performed to examine p53 express-
ion in human tissues. RNA from seven different, morphologically
normal human tissues was isolated (Table 1) and human p53
mRNA was converted to cDNA with primer p96-1 from within
the non-translated region of the p53 gene (Fig. 1A). p53 cDNA
spanning exons 8-11 and part of the non-translated region of the
p53 gene (primers A4 and p96-1) and p53 cDNA including exons
10, 11 and a part of the non-translated region of the p53 gene
(primers p96-l and p96-2) were amplified in separate reactions.
In repeated experiments PCR products of 415 bp (with primers
A4 and p96-l; data not shown) or 170 bp (primers p96-l and
p96-2), respectively, were amplified exclusively (Fig. IB). As
both products represent the NS p53 transcript (38) we did not
obtain evidence for the presence of AS p53 mRNA in human
tissue, similarly to rat tissue.
Comparison of the homologous sequences of exons 10, 11 and
intron 10 of human, rat and mouse p53 genes showed a high
similarity of the exon-intron boundaries, but differences in
sequences and sizes of intron 10 [intron sizes: rat, -700 bp (37);
mouse, 700 bp (39); human, 920 bp (EMBL/GenBank/DDBJ
database accession no. X54156)]. Nevertheless, a potential
alternative 3' splice site with a short polypyrimidine stretch was
detected at almost the same position as the alternative splice site
used in the murine p53 gene, 94 bp further upstream of the 3'
splice site of exon 11, within intron 10 of the human p53 gene
(Fig. 2). This sequence perfectly fits the consensus sequence for
3' splice sites (Table 2). A perfect branch point is located 20 bp
upstream of this potential 3' splice site. If this potential alternative
3' splice site were activated in human tissue its use should lead to
the inclusion of the complete 3' boundary of the last exon within
the alternatively spliced transcript (Fig. 2). In this case RT-PCR
using primers p96-2 and p96-1 should generate an additional PCR
product 264 bp in length (Fig. 2). However, such an additional
product was not detected using this approach, as only a product
of 170 bp, corresponding to the normally spliced p53 mRNA (Fig.
2) was found (Fig. 1B, lane 1). To improve the sensitivity of our
approach RT-PCR specific for this sequence hypothetically
included in an AS human p53 mRNA was performed using
primer p96-4, including the sequence of the 3' boundaries of the
last exon, and primer p96-2, from within exon 10 (Fig. 2;
EMBL/GenBank/DDBJ database accession no. X54156). PCR
conditions were optimized with human genomic DNA and
yielded PCR products of the expected size of 914 bp (data not
shown). If such an alternatively spliced p53 transcript were
present in the RNA of human tissue, RT-PCR using this set of
primers should amplify a cDNA product 88 bp in length (Fig. 2).
However, such a product could not be detected. Since products of
the expected size were amplified from genomic human DNA, but
not from human cDNAs, it is rather unlikely that the failure to
detect the 88 bp cDNA product, representing the postulated
human AS p53 mRNA, is due to the PCR conditions. Instead, we
conclude that this potential splice site in humans is not used, in a
similar fashion as to the corresponding murine splice site.
DISCUSSION
The p53 protein acts as a superior control element in cellular
proliferation. Its multifunctional character is reflected in various
biochemical activities (see Introduction), which require tight
regulation. In regulating the described acitivities the p53 C-
terminus plays a prominent role, as it not only regulates the
sequence-specific DNA binding of p53 mediated by the p53 core
domain, but by itself takes part in a variety of biochemical
activities, which could be regulated by differential expression of
physiologically different variants of p53 with distinct functional
C-terminal ends. An important regulatory element in the C-
terminal domain of p53 is provided by multiple phosphorylation
sites, rendering the C-terminus of p53 a target for a variety of
cellular kinases (24). Alternatively, expression of a C-terminally
shortened p53 variant by alternative splicing has been suggested
as a means of modulating p53 activity. In addition to being
constitutively active in sequence-specific DNA binding, this AS
p53 is devoid of the activities ascribed to the C-terminal domain
(31). Furthermore, by heterocomplex formation with NS p53, AS
p53 could alter the functions of full-length NS p53.
Table 2. Comparison between splice site sequences of exons 10 and 11 of the murine and human p53 gene and the consensus sequence for 3' and 5' splice sites (41,42)
5' Splice sites 3' Splice sites
Consensus sequence
Mouse
Human
AG/GUAAGU
AG/GUAAGU
AG/GUGAGU
YnCAG/G
AS AAUUCCUUUUUUUCAG/CC
NS UUCUGUCUUCCUAUAG/CT
1
 AS' AUUCCCGUUGUCCCAG/CC
NS CUUCUGUCUCCUACAG/CC
Y, pyrimidine; AS, alternative 3' splice site used in the murine p53 gene; 'AS', potential alternative 3' splice site, 94 bp upstream of the 3' splice site of exon 11, within
intron 10 of the human p53 gene; NS, 3' splice site used normally.
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Comparison of the so far available data on p53 genes from
different species revealed that all vertebrate species analyzed
share a high identity at the protein level, as well as a striking
similarity in genomic organization of the p53 gene. We therefore
expected that alternative splicing, which is recognized as an
important means for modulating gene expression (40), would be
a general mechanism for the generation of functionally different
p53 molecules and analyzed the expression pattern of p53
mRNAs in mouse, rat and human tissues. The sizes and sequences
of the exons of the respective p53 genes are quite similar (32).
Although the introns vary in length, they interrupt the exons at
precisely homologous positions. The occurence of similar
splicing events therefore seemed reasonable. However, in con-
trast to this assumption, alternative splicing near the 3'-end of the
p53 transcript was only detected in several mouse tissues, but not
in corresponding tissue specimens of rat and human origin. In the
majority of the mouse tissues analyzed the AS p53 mRNA species
was detected at -25-30% of the level of NS p53 mRNA, in
accordance with previous findings of Han and Kulesz-Martin
(25,26). These transcripts, however, were nearly undetectable in
samples of spleen and kidney tissues of mice. Tissue-specific
differences in the splicing pattern have been reported for several
other genes (36) and could be due to different splicing factors.
Tissue-specific alternative splicing is known to play an important
role in tissue differentiation, for instance in the gene encoding
human neuronal cell adhesion molecules (40). Therefore, our
findings could point to tissue-specific functions for the AS p53
protein in mice.
Screening the known sequences of intron 10 of the human p53
gene for potential alternative splice sites led to the identification
of a candidate splice site at almost the same position as the
alternative 3' splice site used in the murine gene. This splice site
perfectly fits the consensus sequence for 3' splice sites (41,42;
Table 2). Nevertheless, AS p53 mRNA derived from this site was
undetectable, although our approach was sensitive enough
technically to detect the alternatively spliced murine product.
This is exemplified by the fact that we were able to amplify the
corresponding region of the human p53 gene from human
genomic DNA. Thus our failure to detect the much shorter
sequence in the corresponding AS cDNA, which should be
considerably easier to amplify, strongly suggests that the
expected alternative splicing of the p53 transcript in rat and
human is probably a rare event. Alternatively, we cannot exclude
the possibility that the resulting transcripts are less stable and
therefore undetectable.
Our data reveal evolutionary differences in the generation of
variant p53 proteins by alternative splicing which could be due to
changes within the intron sequences, their environment or within
splicing factors, avoiding alternative splicing within this region
or, alternatively, generating an unstable AS p53 RNA. Our study
focused on alternative splicing near the 3'-end of the p53 gene of
rats and humans only. Therefore, we do not want to exclude the
possibility that other alternative splicing events may take place
within other regions of the p53 genes examined. For instance,
Matlashewski and co-workers described an altered transcript
generated by splicing at an alternative acceptor site in intron 2 of
the human p53 gene (43).
Our results raise important questions as to the biological
relevance of alternative splicing of the p53 transcript in mice. AS
p53 mRNA is detected at a substantial level in most of the tissues
analyzed and is translated into a stable AS protein exhibiting quite
different functional properties to the NS p53 protein (27,31). One
has to assume, therefore, that generation of the AS p53 protein in
mice is an important means of regulating p53 activities. The
apparent lack of AS p53 mRNAs in rat and human tissues thus
either indicates functional differences in the NS p53 proteins
between mice and rats and humans or different regulatory
mechanisms. The high conservation of p53 domains within
different species argues against the first alternative. In contrast,
however, different mechanisms for regulation of wild-type p53
activities seem to be an intriguing possibility. This possibility is
also supported by our previous finding of species-specific
phosphorylation of mouse and rat p53 (44).
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